← Back to Clinical Trials
RecruitingPhase 2NCT06485843

An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionOsteoarthritis
SponsorAgeless Biotech, Inc.
Study TypeINTERVENTIONAL
PhasePhase 2
Enrollment400
SexALL
Min Age35 Years
Max Age75 Years
Start Date2025-05-21
Completion2028-03-31
Interventions
OA-SYS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study is being conducted to evaluate the safety and tolerability of OA-SYS in patients with moderate to severe OA of the knee joint.

Eligibility Criteria

Inclusion Criteria: * Adults between the ages of 35 - 75 years Body Mass Index (BMI) less than 39 kg/m2 * Ambulatory and in good general health * Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions * Willing to abstain from use of protocol-restricted treatments from Screening through End-of-Treatment * Kellgren-Lawrence grading scale score of 3 or 4 for OA of the knee * No clinically significant abnormalities observed in medical history, physical exam vital signs, and laboratory assessments * For females of reproductive potential: use of effective contraception for at least 1 month prior to screening and agreement to use such a method till end of the study period and negative pregnancy test * For males of reproductive potential: use of condoms and other methods to ensure effective contraception Exclusion Criteria: * Known or suspected infection of the target joint * Subjects with surgery for OA in the target joint

Related Trials